Αποτελέσματα αναζήτησης - "фебрильная нейтропения"

Πηγή: Head and Neck Tumors (HNT); Том 11, № 3 (2021); 72-82 ; Опухоли головы и шеи; Том 11, № 3 (2021); 72-82 ; 2411-4634 ; 2222-1468 ; 10.17650/2222-1468-2021-11-3

Θεματικοί όροι: эмпэгфилграстим, hematologic toxicity, myelotoxicity, febrile neutropenia, granulocyte colony-stimulating factor, filgrastim, empegfilgrastim, гематологическая токсичность, миелотоксичность, фебрильная нейтропения, гранулоцитарный колониестимулирующий фактор, филграстим

Περιγραφή αρχείου: application/pdf

Relation: https://ogsh.abvpress.ru/jour/article/view/675/491; Nguyen-Tan P.F., Zhang Q., Ang K.K. et al. Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity. J Clin Oncol 2014;32(34):3858–66. DOI:10.1200/JCO.2014.55.3925.; Bonadonna G., Moliterni A., Zambetti M. et al. 30 years’ follow up of randomized study of adjuvant CMF in operable breast cancer: cogort study. BMJ 2005;330:217–20. DOI:10.1136/bmj.38314.622095.8F.; Сакаева Д.Д., Курмуков И.А., Орлова Р.В., Шабаева М.М. Практические рекомендации по диагностике и лечению фебрильной нейтропении. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2 2020;10(39). Доступно по: https://www.rosoncoweb.ru/standarts/RUSSCO/2020/2020-39.pdf. DOI:10.18027/2224-5057-2020-10-3s2-39/; Weycker D., Barron R., Edelsberg J. et al. Risk and consequences of chemotherapyinduced neutropenic complications in patients receiving daily filgrastim: the importance of duration of prophylaxis. BMC Health Serv Res 2014;14:189. DOI:10.1186/1472-6963-14-189.; Cornes P., Gascon P., Chan S. et al. Systematic review and meta-analysis of short-versus long-acting granulocyte colony-stimulating factors for reduction of chemotherapy-induced febrile neutropenia Adv Ther 2018;35(11):1816–29. DOI:10.1007/s12325-018-0798-6.; Криворотько П.В., Бурдаева О.Н., Ничаева М.Н. и др. Эффективность и безопасность препарата Экстимия® (эмпэгфилграстим) у пациентов с диагнозом «рак молочной железы», получающих миелосупрессивную химиотерапию: результаты двойного слепого сравнительного клинического исследования III фазы. Современная онкология 2015;17(2):45–52.; Wang Y., Chen L., Liu F. et al. Efficacy and tolerability of granulocyte colonystimulating factors in cancer patients after chemotherapy: a systematic review and Bayesian network meta-analysis. Sci Rep 2019;9(1):15374. DOI:10.1038/s41598-019-51982-4.; Нестерова Е.С., Клиточенко Т.Ю., Глонина Н.Н. и др. Промежуточные результаты многоцентрового ретроспективно-проспективного наблюдательного пострегистрационного исследования безопасности и эффективности применения препарата Экстимия ЗАО «Биокад» у пациентов с лимфопролиферативными заболеваниями, получающих цитотоксическую терапию. Современная онкология 2020;22(4):77–84. DOI:10.26442.18151434.2020.4.200492.; Lyman G.H., Dale D.C., Culakova E. et al. The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol 2013;24(10):2475–84. DOI:10.1093/annonc/mdt226.; Kuderer N.M., Dale D.C., Crawford J., Lyman G.H. Impact of primary prophylaxis with granulocyte colonystimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007;25(21):3158–67. DOI:10.1200/JCO.2006.08.8823.; Crawford J., Ozer H., Stoller R. et al. Reduction by granulocyte colonystimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164–70. DOI:10.1056/NEJM199107183250305.; Pettengell R., Gurney H., Radford J.A. et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin’s lymphoma: a randomized controlled trial. Blood 1992;80(6):1430–6.; Trillet-Lenoir V., Green J., Manegold C. et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993;29A(3):319–24. DOI:10.1016/0959-8049(93)90376-q.; Zinzani P.L., Pavone E., Storti S. et al. Randomized trial with or without granulocyte colonystimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin’s lymphoma. Blood 1997;89(11):3974–9.; Fossa S.D., Kaye S.B., Mead G.M. et al. Filgrastim during combination chemotherapy of patients with poorprognosis metastatic germ cell malignancy: European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol 1998;16(2):716–24. DOI:10.1200/JCO.1998.16.2.716.; Doorduijn J.K., van der Holt B., van Imhoff G.W. et al. CHOP compared with CHOP plus granulocyte colonystimulating factor in elderly patients with aggressive non-Hodgkin’s lymphoma. J Clin Oncol 2003;21(16):3041–50. DOI:10.1200/JCO.2003.01.076.; Osby E., Hagberg H., Kvaloy S. et al. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood 2003;101(10):3840–8. DOI:10.1182/blood-2002-10-3238.; Timmer-Bonte J.N., de Boo T.M., Smit H.J. et al. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: A Dutch randomized phase III study. J Clin Oncol 2005;23(31):7974–84. DOI:10.1200/JCO.2004.00.7955.; Chevallier B, Chollet P, Merrouche Y, et al. Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J Clin Oncol 1995;13(7):1564–71. DOI:10.1200/jco.1995.13.7.1564.; Bui B.N., Chevallier B., Chevreau C. et al. Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity. J Clin Oncol 1995;13(10):2629–36. DOI:10.1200/JCO.1995.13.10.2629.; Gisselbrecht C., Haioun C., Lepage E. et al. Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive nonHodgkin’s lymphoma: factors influencing chemotherapy administration – Groupe d’Etude des Lymphomes de l’Adulte. Leuk Lymphoma 1997;25(3–4):289–300. DOI:10.3109/10428199709114168.; Gatzemeier U., Kleisbauer J.P., Drings P. et al. Lenograstim as support for ACE chemotherapy of small-cell lung cancer: a phase III, multicenter, randomized study. Am J Clin Oncol 2000;23(4):393–400.; Vogel C.L., Wojtukiewicz M.Z., Carroll R.R. et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebocontrolled phase III study. J Clin Oncol 2005;23(6):1178–84. DOI:10.1200/JCO.2005.09.102.; Su Y.B., Vickers A.J., Zelefsky M.J. et al. Double-blind, placebo-controlled, randomized trial of granulocytecolony stimulating factor during postoperative radiotherapy for squamous head and neck cancer. Avaliable at: https://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.487.9730&rep=rep1&type=pdf.; Gawade P., Li S., Henry D. et al. Patterns of granulocyte colony-stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy Suppor Care Cancer 2020:28(9):4413–24. DOI:10.1007/s00520-020-05295-2.; Linot B., Augereau P., Breheret R., Laccourreye L., Capitain O. Efficacy and safety of early G-CSF administration in patients with head and neck cancer treated by docetaxel-cisplatin and 5-fluorouracil (DCF protocol): a retrospective study. Support Care Cancer 2014;22(10):2831–7. DOI:10.1007/s00520-014-2270-8.; https://ogsh.abvpress.ru/jour/article/view/675

Διαθεσιμότητα: https://ogsh.abvpress.ru/jour/article/view/675
https://doi.org/10.17650/2222-1468-2021-11-3-72-82

View record from BASE

4

Academic Journal

Практические рекомендации по диагностике и лечению фебрильной нейтропении

Συγγραφείς: Д. Д. Сакаева, И. А. Курмуков, Р. В. Орлова, М. М. Шабаева

Πηγή: Malignant tumours; Том 10, № 3s2-2 (2020); 45-51 ; Злокачественные опухоли; Том 10, № 3s2-2 (2020); 45-51 ; 2587-6813 ; 2224-5057

Θεματικοί όροι: колониестимулирующие факторы, противоопухолевая терапия, нежелательное явление, фебрильная нейтропения, антибиотикотерапия

Περιγραφή αρχείου: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/790/554; https://www.malignanttumors.org/jour/article/view/790

Διαθεσιμότητα: https://www.malignanttumors.org/jour/article/view/790
https://doi.org/10.18027/2224-5057-2020-10-3s2-39

View record from BASE

5

Academic Journal

Should to all patients with febrile neutropenia and colonization with extended-spectrum β-lactamase-producing Enterobacteriaceae carbapenems be appointed?

Συγγραφείς: V. A. Okhmat, G. A. Klyasova, A. G. Korobova, E. N. Parovichnikova, A. V. Fedorova, V. V. Troitskaya, E. O. Gribanova, V. G. Savchenko

Πηγή: Онкогематология, Vol 11, Iss 3, Pp 49-57 (2016)

Θεματικοί όροι: 03 medical and health sciences, 0302 clinical medicine, Diseases of the blood and blood-forming organs, фебрильная нейтропения, антибиотики, RC633-647.5, β-лактамазы расширенного спектра, колонизация, острый лейкоз, 3. Good health

Σύνδεσμος πρόσβασης: https://oncohematology.abvpress.ru/ongm/article/download/206/207
https://doaj.org/article/9848ec74d2f14eb6a7c212569f4dcb02
http://oncohematology.abvpress.ru/ongm/article/download/206/207
https://oncohematology.abvpress.ru/ongm/article/view/206
https://oncohematology.abvpress.ru/ongm/article/download/206/207
https://core.ac.uk/display/87479486
https://cyberleninka.ru/article/n/sleduet-li-naznachat-karbapenemy-vsem-bolnym-s-febrilnoy-neytropeniey-i-kolonizatsiey-enterobakteriyami-s-produktsiey-laktamaz

View record at OpenAIRE Full Text Finder

6

Academic Journal

ПРЕИМУЩЕСТВА И НЕДОСТАТКИ ИСПОЛЬЗОВАНИЯ ПРОКАЛЬЦИТОНИНА В КЛИНИКЕ

Συγγραφείς: Н. С. Багирова, И. Н. Петухова, З. В. Григорьевская, И. В. Терещенко, Н. В. Дмитриева

Πηγή: Malignant tumours; Том 9, № 3s1 (2019); 32-42 ; Злокачественные опухоли; Том 9, № 3s1 (2019); 32-42 ; 2587-6813 ; 2224-5057

Θεματικοί όροι: фебрильная нейтропения, онкологические пациенты, сепсис

Περιγραφή αρχείου: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/662/455; Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit.Care 2010;14: R15. DOI:10.1186/cc8872; de Jong E, van Oers JA, Beishuizen A, Vos P, Vermeijden WJ, Haas LE, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, openlabel trial. Lancet Infect Dis 2016;16:819e27. http://dx.doi.org/10.1016/; Bonita Durnaś, Marzena Wątek, Tomasz- Wollny, Katarzyna Niemirowicz, Michał Marzec, Robert Bucki, Stanisław Góźdź. Utility of blood procalcitonin concentration in the management of cancer patients with infections. OncoTargets and Therapy 2016;9:469–475. http://dx.doi.org/10.2147/OTT.S95 600; Maruna P, Nedelnikova K, Gurlich R. Physiology and genetics of procalcitonin. Physiol Res. 2000;49 (Suppl 1):S57 — S61. https://doi.org/10.2147/OTT.S95600; Hochreiter M., Kohler T., Schweiger A. et al. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Critical Care, 2009;13 (3): R83 doi:10.1186/cc7903.; Brunkhorst F.M., Forycki Z.F., Wagner J . Identif ication of immunoactivation of infectious origin by procalcitonin in body fluids [Abstract]. In: First International Symposium in Iena of Intensive Care Medicine, 1996. Clin. Intensive Care Suppl. 7/1.; Leon A., Lepouse C., Cousson J., et al. Procalcitonin in pleural effusion as a marker of septic response. [Abstract]. In: Fifth Vienna Shock Forum, 1995; GBD 2015 LRI Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Infect Dis 2017; published online Aug http://dx.doi.org/10.1016/S1473–3099(17)30396–1; Shapiro DJ, Hicks LA, Pavia AT, Hersh AL. Antibiotic prescribing for adults in ambulatory care in the USA, 2007–09. J Antimicrob Chemother 2014; 69: 234–40. doi:10.1093/jac/dkt301; Jain S, Self WH, Wunderink RG, et al. Community-acquired pneumonia requiring hospitalization among US adults. N Engl J Med 2015; 373: 415–27. doi:10.1056/NEJMoa1 500 245; Stolz D, Christ-Crain M, Bingisser R, Leuppi J, Miedinger D, Muller C, Huber P, Muller B, Tamm M. Antibiotic treatment of exacerbations; of COPD: a randomized, controlled trial comparing procalcitoninguidance with standard therapy. Chest. 2007 Jan;131 (1):9–19. DOI:10.1378/chest.06–1500; Schuetz P, Muller B, Christ-Crain M, et al. Procalcitonin to initiate or discontinue antibiotics in acute respirator y tract infections. Cochrane Database Syst Rev 2012;9: CD007 498. doi:10.1002/14651858.CD007498.pub3; Garnacho-Montero J, Gutierrez-Pizarraya A, Escoresca-Ortega A, et al. Deescalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock. Intensive Care Med 2014; 40:32–40. doi:10.1007/s00134‑013‑3077‑7; Schuetz P, Balk R, Briel M, et al. Economic evaluation of procalcitonin-guided antibiotic therapy in acute respiratory infections: a US health system perspective. Clin Chem Lab Med 2015; 53:583–592. doi:10.1515/cclm-2014–1015; Stojanovic I, Schneider JE, Wei L, et al. Economic evaluation of procalcitoninguided antibiotic therapy in acute respiratory infections: a Chinese hospital system perspective. Clin Chem Lab Med 2017; 55:561–570. doi:10.1515/cclm-2016–0349; Schuetz P, Wirz Y, Sager R, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev 2017; 10: CD007 498. doi:10.1002/14651858.CD007498.pub3; Schuetz P, Wirz Y, Sager R, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level metaanalysis. Lancet Infect Dis 2018; 18:95–107. doi:10.1016/S1473–3099 (17) 30 592–3.; Branche Angela, Neeser Olivia, Mueller Beat, Schuetz Philipp. Procalcitonin to guide antibiotic decision making. RESPIRATORY INFECTIONS: Edited by Michael S. Niederman: Curr Opin Infect Dis 2019; 32:130–135. DOI:10.1097/QCO.0000000000000522; Schuetz P, Kutz A, Grolimund E, et al. Excluding infection through procalcitonin testing improves outcomes of congestive heart failure patients presenting with acute respiratory symptoms: results from the randomized ProHOSP trial. Int J Cardiol 2014; 175:464–472. doi:10.1016/j.ijcard.2014.06.022.; Schuetz P, Daniels LB, Kulkarni P, et al. Procalcitonin: a new biomarker for the cardiologist. Int J Cardiol 2016; 223:390–397. doi:10.1016/j.ijcard.2016.08.204; Llewelyn MJ, Fitzpatrick JM, Darwin E, et al. The antibiotic course has had its day. BMJ 2017; 358: j3418. doi:10.1136/bmj.j3418; Schuetz P, Mueller B. Biomarker-guided de-escalation of empirical therapy is associated with lower risk for adverse outcomes. Intensive Care Med 2014;40:141. doi:10.1007/s00134‑013‑3139‑x.; Carr JA. Procalcitonin-guided antibiotic therapy for septic patients in the surgical intensive care unit. Journal of Intensive Care, 2015; 3: 36. doi:10.1186/s40560‑015‑0100‑9.; Schuetz P., Chiappa V., Briel et al. Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Archives of Internal Medicine, 2011; 171 (15): 1322–1331. doi:10.1001/archinternmed.2011.318; Nobre V, Harbar th S, Graf JD, et al. Use of procalcitonin to shor ten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med 2008; 177:498–505. DOI:10.1164/rccm.200708-1238OC; Schuetz P, Birkhahn R, Sherwin R, et al. Serial procalcitonin predicts mortality in severe sepsis patients: results from the multicenter procalcitonin Monitoring SEpsis (MOSES) study. Crit Care Med 2017; 45:781–789. doi:10.1097/CCM.0 000 000 000; 321; van der Does Y, Limper M, Jie KE, et al. Procalcitonin-guided antibiotic therapy in patients with fever in a general emergency department population: a multicentre noninferiority randomized clinical trial (HiTEMP study). Clin Microbiol Infect 2018; 24:1282–1289. doi:10.1016/j.cmi.2018.05.011.; Schuetz P, Falsey AR. Procalcitonin in patients with fever: one approach does not fit all. Clin Microbiol Infect 2018; 24:1229–1230. doi:10.1016/j.cmi.2018.07.022; Huang DT, Yealy DM, Filbin MR, Brown AM, Chang CH, Doi Y, et al. Procalcitonin-guided use of antibiotics for lower respiratory tract infection. N Engl J Med 2018; 379:236–249. doi:10.1056/NEJMoa1802670; Reynolds SC, Shorr AF, Muscedere J , Jiang X, Heyland DK. Longitudinal changes in procalcitonin in a heterogeneous group of critically ill patients. Crit Care Med 2012; 40: 2781–87. DOI:10.1097/CCM.0b013e31 825b89cc; Ferrer R, Martin-Loeches I, Phillips G, et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program. Crit Care Med 2014; 42: 1749–55. doi:10.1097/CCM.0 000 000 000 000 330; Gaieski DF, Mikkelsen ME, Band RA, et al. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med 2010; 38: 1045–53. doi:10.1097/CCM.0b013e3181cc4824; Fontela PS, Quach C, Karim ME, et al. Determinants of antibiotic tailoring in pediatric intensive care: a national survey. Pediatr Crit Care Med 2017; 18: e395 — e405. doi:10.1097/PCC.0 000 000 000 001 238; Cremieux AC, Muller-Serieys C, Panhard X, et al. Emergence of resistance in normal human aerobic commensal flora during telithromycin and amoxicillin-clavulanic acid treatments. Ant imicrob Agents Chemother 2003; 47: 2030–35. doi; 1128/AAC.47.6.2030–2035.2003; van Bijnen EME, Paget J, de Lange-de Klerk ESM, et al. Antibiotic exposure and other risk factors for antimicrobial resistance in nasal commensal Staphylococcus aureus: an ecological study in 8 European countries. PLoS One 2015; 10: e0 135 094. doi.org/10.1371/journal.pone.0 135 094; Dubos F., Korczowski B., Aygun D.A. et al. Distinguishing between bacterial and aseptic meningitis in children: European comparison of two clinical decision rules. Arch. Dis. Child., 2010; 95: 963–967. DOI:10.1136/adc.2010.186056; Leroy S., Gervaix A. Procalcitonin: a key marker in children with urinary tract infection. Adv. Urol., 2011;397 618 21 274 426. doi:10.1155/2011/397618; Galetto-Lacour A., Alcoba G., Posfay-Barbe K.M. et al. Elevated inflammatory markers combined with positive pneumococcal urinary antigen are a good predictor of pneumococcal communityacquired pneumonia in children. Pediatr. Infect. Dis J., 2013; 32 (11): 1175–1179. doi:10.1097/INF.0b013e31 829ba62a; Westwood ME, Ramaekers BLT, Whiting P, Tomini F, Joore MA, Armstrong N, et al. Procalcitonin testing to guide antibiotic therapy for the treatment of sepsis in intensive care settings and for suspected bacterial infection in emergency department settings: a systematic review and cost-effectiveness analysis. Health Technol Assess 2015;19 (96). DOI:10.3310/hta19960; Mewes JC, Pulia MS, Mansour MK, Broyles MR, Nguyen HB, Steuten LM (2019) The cost impact of PCT-guided antibiotic stewardship versus usual care for hospitalised patient s with suspected sepsis or lower respiratory tract infections in the US: A health economic model analysis. PLoS ONE 14 (4): e0 214 222. https://doi.org /10.1371/journal.pone.0214222; Iankova I, Thompson-Leduc P, Kirson NY, Rice B, Hey J, Krause A, et al. Efficacy and safety of procalcitonin guidance in patients with suspected or confirmed sepsis: a systematic review and metaanalysis. Crit Care Med. 2018;46:691–698. doi:10.1097/CCM.0 000 000 000 002 928.; Patout M, Salaun M, B runel V, Bota S , Caul ie z B , Thiberville L. Diag¬nostic and prognostic value of serum procalcitonin concentrations in primary lung cancers. Clin Biochem. 2014;47 (18):263–267. doi:10.1016/j.clinbiochem.2014.09.002; Schuttrumpf S, Binder L, Hagemann T, Berkovic D, Trumper L, Binder C. Utility of procalcitonin concentration in the evaluation of patients with malignant diseases and elevated C-reactive protein plasma concentrations. Clin Infect Dis. 2006;43 (4):468–473. DOI:10.1086/505 394; Schuetz P.B., Mueller, A. Trampuz. Contamination from Bloodstream Infection due to Coagulase-Negative Staphylococci. Infection, 2007, 35 (5): 352–355. DOI 10.1007/s15010‑007‑7065‑0; Müller F, Christ-Crain M, Bregenzer T, et al. Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: A prospective cohort trial. Chest, 2010, 138: 121–129. DOI:10.1378/chest.09–2920; Hanine El Haddad, Anne-Marie Chaftari, Ray Hachem, Patrick Chaftari, and Issam I. Raad. Biomarkers of Sepsis and Bloodstream Infections: The Role of Procalcitonin and Proadrenomedullin With Emphasis in Patients With Cancer. Clinical Infectious Diseases® 2018;67 (6):971–7. DOI:10.1093/cid/ciy331; Matzaraki V, Alexandraki KI, Venetsanou K, et al. Evaluation of serum procalcitonin and interleukin-6 levels as markers of liver metastasis. Clin Biochem 2007;40:336–42. DOI:10.1016/j.clinbiochem.2006.10.027; Chaftari AM, Hachem R, Reitzel R, et al. Role of procalcitonin and interleukin-6 in predicting cancer, and its progression independent of infection. PLOS One 2015; 10: e0 130 999. doi:10.1371/journal.pone.0130999; Ilhan N, Ilhan N, Ilhan Y, Akbulut H, Kucuksu M. C-reactive protein, procalcitonin, interleukin-6, vascular endothelial growth factor and oxidative metabolites in diagnosis of infection and staging in patients with gastric cancer. World J Gastroenterol 2004; 10:1115–20. DOI:10.3748/wjg.v10.i8.1115; Ittner L, Born W, Rau B, Steinbach G, Fischer JA. Circulating procalcitonin and cleavage products in septicaemia compared with medullary thyroid carcinoma. Eur J Endocrinol 2002; 147:727–31. DOI:10.1530/eje.0.1 470 727; Avrillon V, Locatelli-Sanchez M, Folliet L, et al. Lung cancer may increase serum procalcitonin level. Infect Disord Drug Targets 2015; 15:57–63.; Shen H, Zheng S, Chen R, et al. Prognostic significance of serum procalcitonin in patients with unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization: a retrospective analysis of 509 cases. Medicine (Baltimore) 2017; 96: e7438. doi:10.1097/MD.0 000 000 000 007 438; Chen L, Zhang Y, Lin Y, et al. The role of elevated serum procalcitonin in neuroendocrine neoplasms of digestive system. Clin Biochem 2017; 50:982–7. doi:10.1016/j.clinbiochem.2017.06.010; Yaegashi H, Izumi K, Kitagawa Y, et al. Differential diagnosis between bacterial infection and neoplastic fever in patients with advanced urological cancer: the role of procalcitonin. Int J Urol 2014; 21:104–6. doi:10.1111/iju.12 178.; Shomali W, Hachem R, Chaftari AM, et al. Can procalcitonin distinguish infectious fever from tumor-related fever in nonneutropenic cancer patient s? Cancer 2012; 118:5823–9. doi:10.1002/cncr.27 602.; Gac AC, Parienti JJ, Chantepie S, et al. Dynamics of procalcitonin and bacteremia in neutropenic adults with acute myeloid leukemia. Leuk Res. 2011;35 (10):1294–1296. doi:10.1016/j.leukres.2011; Carnino L, Betteto S, Loiacono M, et al. Procalcitonin as a predictive marker of infections in chemoinduced neutropenia. J Cancer Res Clin Oncol. 2010;136 (4):611–615. doi:10.1007/s00432‑009‑0699‑9; Al Shuaibi M, Bahu RR, Chaftari AM, et al. Pro-adrenomedullin as a novel biomarker for predicting infections and response to antimicrobials in febrile patients with hematologic malignancies. Clin Infect Dis 2013; 56:943–50. doi:10.1093/cid/cis1029; Lucena CM, Rovira M, Gabarrus A, et al. The clinical value of biomarkers in respiratory complications in hematopoietic SCT. Bone Marrow Transplant 2017;52:415–22. doi:10.1038/bmt.2016.280; Debiane L, Hachem RY, Al Wohoush I, et al. The utility of proadrenomedullin and procalcitonin in comparison to C-reactive protein as predictors of sepsis and bloodstream infections in critically ill patients with cancer*. Crit Care Med 2014; 42:2500–7. doi:10.1097/CCM.0 000 000 000 000 526; Rast AC, Kutz A, Felder S, et al. Procalcitonin improves the Glasgow Prognostic Score for outcome prediction in emergency patients with cancer: a cohort study. Dis Markers 2015; 2015:795 801. doi:10.1155/2015/795 801; Ahn S, Lee YS, Lim KS, Lee JL. Adding procalcitonin to the MASCC risk-index score could improve risk stratification of patients with febrile neutropenia. Support Care Cancer 2013; 21:2303–8. doi:10.1007/s00 520‑013‑1787‑6; Lima SS, Nobre V, de Castro Romanelli RM, et al. Procalcitoninguided protocol is not useful to manage antibiotic therapy in febrile neutropenia: a randomized controlled trial. Ann Hematol 2016; 95:1169–76. doi:10.1007/s00277‑016‑2639‑5; Haddad HE, Chaftari AM, Hachem R, et al. Procalcitonin guiding antimicrobial therapy duration in febrile cancer patients with documented infection or neutropenia. Sci Rep 2018; 8:1099. doi:10.1038/s41 598‑018‑19 616‑3; Lehrnbecher T, Robinson P, Fisher B, Alexander S, Ammann RA, BeaucheminM, Carlesse F, Groll AH, Haeusler GM, Santolaya M, Steinbach WJ, Castagnola E, Davis BL, Dupuis LL, Gaur AH, Tissing WJE, Zaoutis T, Phillips R, Sung L. Guideline for the management of fever and neutropenia in children with cancer and hematopoietic stem-cell transplantation recipients: 2017 update. J Clin Oncol 2017; 35:2082–2094. https://doi.org /10.1200/JCO.2016.71.7017; Miedema KGE, De Bont ESJM, Elferink RFMO et al. The diagnostic value of CRP, IL-8, PCT, and sTREM-1 in the detection of bacterial infections in pediatric oncology patients with febrile neutropenia. Support Care Cancer. 2011; 19:1593–1600. https://doi.org/10.1007/s00 520‑010‑0987‑6; Hodgson-Viden H, Grundy PE, Robinson JL et al . Early discontinuation of intravenous antimicrobial therapy in pediatric oncology patients with febrile neutropenia. BMC Pediatr. 2005; 5:10. https://doi.org/10.1186/1471‑2431‑5‑10; Hilde T. van der Galiën & Erik A.H. Loeffen & Karin G.E. Miedema1& Wim J.E. Tissing. Predictive value of PCT and IL-6 for bacterial infection in children with cancer and febrile neutropenia. Supportive Care in Cancer. 2018; 26:3819–3826. https://doi.org/10.1007/s00 520‑018‑4249‑3; https://www.malignanttumors.org/jour/article/view/662

Διαθεσιμότητα: https://www.malignanttumors.org/jour/article/view/662
https://doi.org/10.18027/2224-5057-2019-9-3s1-32-42

View record from BASE

7

Academic Journal

ECTHYMA GANGRENOSUM AND SEPTIC SHOCK CAUSED BY PSEUDOMONAS AERUGINOSA IN A CYTOTOXIC NEUTROPENIC PATIENT ; ECTHYMA GANGRENOSUM И СЕПТИЧЕСКИЙ ШОК, ВЫЗВАННЫЕ СИНЕГНОЙНОЙ ПАЛОЧКОЙ У БОЛЬНОЙ В СОСТОЯНИИ ЦИТОТОКСИЧЕСКОЙ НЕЙТРОПЕНИИ

Συγγραφείς: I. A. Kurmukov, Sh. R. Kashiya, O. A. Obukhova, N. V. Dmitrieva, И. А. Курмуков, Ш. Р. Кашия, О. А. Обухова, Н. В. Дмитриева

Πηγή: Journal Infectology; Том 9, № 3 (2017); 134-138 ; Журнал инфектологии; Том 9, № 3 (2017); 134-138 ; 2072-6732 ; 10.22625/2072-6732-2017-9-3

Θεματικοί όροι: фебрильная нейтропения, Pseudomonas aeruginosa, sepsis, chemotherapy, chemotherapy-association complications, febrile neutropenia, сепсис, противоопухолевая терапия, осложнения лекарственного лечения

Περιγραφή αρχείου: application/pdf

Relation: https://journal.niidi.ru/jofin/article/view/643/569; Weiner, L.M. Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014. / L.M. Weiner [et al.] // Infect Control Hosp Epidemiol. – 2016. – 37. – P. 1288-1301.; Sanders, C.V. The Skin and Infection: A Color Atlas and Text. // In: C.V. Sanders, eds. – Baltimore, MD: Williams & Wilkins. – 1995. – P. 296-305.; Курмуков, И.А. Экссудативный онихолизис как осложнение противоопухолевого лечения паклитакселом в режиме еженедельного введения: собственные наблюдения / И.А. Курмуков [и др.] // Онкогинекология. – 2017. – № 1(21) – С. 63–69.; Klastersky, J. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines / J. Klastersky [et al.] // Annals of Oncology. – 2016. – 27. – (Suppl. 5). – P. 111–118.; Sarkar, S. Ecthyma gangrenosum in the periorbital region in a previously healthy immunocompetent woman without bacteremia. / S. Sarkar [et al.] // Indian Dermatol Online J. – 2016. – Vol. 7, № 1. – P. 36–39.; Reich, H.L. Nonpseudomonal ecthyma gangrenosum. / H.L. Reich [et al.] // J Am Acad Dermatol. – 2004. – Vol. 50, № 5. – P.114-117.; Yan, W. Ecthyma gangrenosum and multiple nodules: cutaneous manifestations of Pseudomonas aeruginosa sepsis in a previously healthy infant. / W. Yan [et al.] // Pediatr. Dermatol. – 2011. – Vol. 28, № 2. – P. 204-205.; Bettens, S. Ecthyma gangrenosum in a non-neutropaenic, elderly patient: case report and review of the literature. / S. Bettens [et al.] // Acta Clin Belg. –2008. – Vol. 63, № 6. – P.394397. 9. Bodey, G.P. Pseudomonas bacteremia. Retrospective analysis of 410 episodes. / G.P. Bodey [et al.] // Arch Intern Med. – 1985. – Vol. 145, № 9. – P. 1621-1629.; https://journal.niidi.ru/jofin/article/view/643

Διαθεσιμότητα: https://journal.niidi.ru/jofin/article/view/643
https://doi.org/10.22625/2072-6732-2017-9-3-134-138

View record from BASE

8

Academic Journal

Сопроводительное лечение осложнений химиотерапии онкологических больных

Συγγραφείς: РЕНКЕ А.Л., ЖЕЖЕР А.А., ШЛАПАК И.П.

Θεματικοί όροι: ФЕБРИЛЬНАЯ НЕЙТРОПЕНИЯ,АНТИБАКТЕРИАЛЬНАЯ ТЕРАПИЯ,ФЕБРИЛЬНА НЕЙТРОПЕНіЯ,АНТИБАКТЕРіАЛЬНА ТЕРАПіЯ,FEBRILE NEUTROPENIA,ANTIBACTERIAL THERAPY

Περιγραφή αρχείου: text/html

Διαθεσιμότητα: http://cyberleninka.ru/article/n/soprovoditelnoe-lechenie-oslozhneniy-himioterapii-onkologicheskih-bolnyh
http://cyberleninka.ru/article_covers/16490884.png

View record from BASE

9

Academic Journal

ЦЕФПИРОМ. ОБЗОР ЛИТЕРАТУРЫ

Συγγραφείς: Дмитриева, Наталья

Θεματικοί όροι: ЦЕФПИРОМ, ЦЕФЕПИМ, НОЗОКОМИАЛЬНЫЕ ИНФЕКЦИИ, СЕПСИС, ФЕБРИЛЬНАЯ НЕЙТРОПЕНИЯ, РЕЗИСТЕНТНОСТЬ К АНТИБИОТИКАМ, ЛЕЧЕНИЕ ГРАМОТРИЦАТЕЛЬНЫХ ИНФЕКЦИЙ, ЦЕФАЛОСПОРИНЫ 4-ГО ПОКОЛЕНИЯ

Περιγραφή αρχείου: text/html

Διαθεσιμότητα: http://cyberleninka.ru/article/n/tsefpirom-obzor-literatury
http://cyberleninka.ru/article_covers/15682337.png

View record from BASE

10

Academic Journal

АЛГОРИТМ РАСПОЗНАВАНИЯ СИНДРОМА СИСТЕМНОГО ВОСПАЛИТЕЛЬНОГО ОТВЕТА ПРИ ФЕБРИЛЬНОЙ НЕЙТРОПЕНИИ У ДЕТЕЙ СО ЗЛОКАЧЕСТВЕННЫМИ НОВООБРАЗОВАНИЯМИ И ГЕМОБЛАСТОЗАМИ

Συγγραφείς: В. В. Дмитриев, А. М. Какунин, И. А. Дунаев, В. М. Захаревич

Θεματικοί όροι: фебрильная нейтропения, синдром системного воспалительного ответа, прокальцито- нин, Ц-реактивный протеин

Περιγραφή αρχείου: text/html

Διαθεσιμότητα: http://cyberleninka.ru/article/n/algoritm-raspoznavaniya-sindroma-sistemnogo-vospalitelnogo-otveta-pri-febrilnoy-neytropenii-u-detey-so-zlokachestvennymi
http://cyberleninka.ru/article_covers/16051727.png

View record from BASE

11

Academic Journal

Сравнительная эффективность моксифлоксацина и ципрофлоксацина при профилактике фебрильной нейтропении (ФН) у онкогематологических больных

Συγγραφείς: Григорьевская, З.

Θεματικοί όροι: ФЕБРИЛЬНАЯ НЕЙТРОПЕНИЯ, ПРОФИЛАКТИКА ИНФЕКЦИЙ, МОКСИФЛОКСАЦИН, ЦИПРОФЛОКСАЦИН

Περιγραφή αρχείου: text/html

Διαθεσιμότητα: http://cyberleninka.ru/article/n/sravnitelnaya-effektivnost-moksifloksatsina-i-tsiprofloksatsina-pri-profilaktike-febrilnoy-neytropenii-fn-u-onkogematologicheskih
http://cyberleninka.ru/article_covers/8643109.png

View record from BASE

12

Academic Journal

АНТИБАКТЕРИАЛЬНАЯ ТЕРАПИЯ В ЛЕЧЕНИИ ФЕБРИЛЬНОЙ НЕЙТРОПЕНИИ У ДЕТЕЙ

Συγγραφείς: Галеева, А., Гайнуллина, Э.

Θεματικοί όροι: ФЕБРИЛЬНАЯ НЕЙТРОПЕНИЯ, ТЕРАПИЯ, АНТИБИОТИКИ

Περιγραφή αρχείου: text/html

Διαθεσιμότητα: http://cyberleninka.ru/article/n/antibakterialnaya-terapiya-v-lechenii-febrilnoy-neytropenii-u-detey
http://cyberleninka.ru/article_covers/15464080.png

View record from BASE

13

Academic Journal

Supporting Treatment of Chemotherapy Complications in Oncological Patients

Συγγραφείς: Renke, A.L., Zhezher, A.A., Shlapak, I.P.

Πηγή: EMERGENCY MEDICINE; № 1.64 (2015); 20-26
МЕДИЦИНА НЕОТЛОЖНЫХ СОСТОЯНИЙ; № 1.64 (2015); 20-26
МЕДИЦИНА НЕВІДКЛАДНИХ СТАНІВ; № 1.64 (2015); 20-26

Θεματικοί όροι: febrile neutropenia, antibacterial therapy, фебрильна нейтропенія, антибактеріальна терапія, фебрильная нейтропения, антибактериальная терапия

Περιγραφή αρχείου: application/pdf

Σύνδεσμος πρόσβασης: http://emergency.zaslavsky.com.ua/article/view/79539

View record at OpenAIRE

14

Academic Journal